Synergistic Neuroprotective Effects of Lithium and Valproic Acid or Other Histone Deacetylase Inhibitors in Neurons: Roles of Glycogen Synthase Kinase-3 Inhibition
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Lithium and valproic acid (VPA) are two primary drugs used to treat bipolar mood disorder and have frequently been used in combination to treat bipolar patients resistant to monotherapy with either drug. Lithium, a glycogen synthase kinase-3 (GSK-3) inhibitor, and VPA, a histone deacetylase (HDAC) inhibitor, have neuroprotective effects. The present study was undertaken to demonstrate synergistic neuroprotective effects when both drugs were coadministered. Pretreatment of aging cerebellar granule cells with lithium or VPA alone provided little or no neuroprotection against glutamate-induced cell death. However, copresence of both drugs resulted in complete blockade of glutamate excitotoxicity. Combined treatment with lithium and VPA potentiated serine phosphorylation of GSK-3 α and β isoforms and inhibition of GSK-3 enzyme activity. Transfection with GSK-3α small interfering RNA (siRNA) and/or GSK-3β siRNA mimicked the ability of lithium to induce synergistic protection with VPA. HDAC1 siRNA or other HDAC inhibitors (phenylbutyrate, sodium butyrate or trichostatin A) also caused synergistic neuroprotection together with lithium. Moreover, combination of lithium and HDAC inhibitors potentiated β-catenin-dependent, Lef/Tcf-mediated transcriptional activity. An additive increase in GSK-3 serine phosphorylation was also observed in mice chronically treated with lithium and VPA. Together, for the first time, our results demonstrate synergistic neuroprotective effects of lithium and HDAC inhibitors and suggest that GSK-3 inhibition is a likely molecular target for the synergistic neuroprotection. Our results may have implications for the combined use of lithium and VPA in treating bipolar disorder. Additionally, combined use of both drugs may be warranted for clinical trials to treat glutamate-related neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GSK-3: tricks of the trade for a multi-tasking kinase
Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084 · cited 1×
“GSK-3 is generally considered to have a proapoptotic role, and its inhibition results in cytoprotection (for review, see Bijur and Jope, 2003; Doble and Woodgett, 2003).”
BackgroundPhiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758 · cited 5×
“In contrast, other studies suggested that this drug fails to affect GSK-3 activity (Phiel et al., 2001; Hall et al., 2002; Eickholt et al., 2005; Jin et al., 2005).”
BackgroundResultInfluentialLithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321
Recovery of learning and memory is associated with chromatin remodelling
Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., & Tsai, L.-H. (2007) · Nature · doi:10.1038/nature05772 · Cited by 1,227 · cited 1×
“HDAC inhibitors have also been shown to enhance learning, memory, and synaptic plasticity through chromatin remodeling and cAMP response elementbinding protein (CREB):CREB binding protein-dependent transcriptional activation (Fischer et al., 2007; Vecsey et al., 2007).”
BackgroundThe cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182 · cited 1×
“…most likely through GSK-3 inhibition, enhance cellular resilience and plasticity and, in turn, contribute to their clinical efficacy (for review, see Manji et al., 2001; Bachmann et al., 2005), although additional longitudinal clinical studies are required to firmly establish this linkage.”
BackgroundDrevets, W. C. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00203-8 · Cited by 1,146 · cited 2×
“Protracted treatments of bipolar patients with lithium or VPA have been found to suppress the loss of gray matter volume in the prefrontal cortex and amygdala compared with patients receiving no such treatment (Drevets, 2001; Chang et al., 2005).”
BackgroundNoble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709 · cited 2×
“, 2003), lowers the phosphorylation and aggregation of Tau protein (Noble et al., 2005), and provides neuroprotective effects in APP transgenic mice (Rockenstein et al.”
BackgroundLithium-induced increase in human brain grey matter
Moore, G. J., Bebchuk, J. M., Wilds, I. B., Chen, G., & Menji, H. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02793-8 · Cited by 649 · cited 2×
“DOI:10.1523/JNEUROSCI.5467-07.2008 Copyright © 2008 Society for Neuroscience 0270-6474/08/282576-13$15.00/0 aspartate, a marker of neuronal viability, in the brain of bipolar patients (Moore et al., 2000b).”
BackgroundInfluentialYasuda, S., Liang, M.-H., Marinova, Z., Yahyavi, A., & Chuang, D.-M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002099 · Cited by 358
Self-citationPolytherapy in Bipolar Disorder
Lin, D., Mok, H., & Yatham, L. N. (2006) · CNS Drugs · doi:10.2165/00023210-200620010-00003 · Cited by 91 · cited 4×
“Several atypical antipsychotic drugs have also been used in conjunction with lithium or VPA to maximize the clinical efficacy for bipolar disorder (for review, see Freeman and Stoll, 1998; Zarate and Quiroz, 2003; Bachmann et al., 2005; Lin et al., 2006).”
BackgroundMethodInfluential
Cited by
Multiple roles of HDAC inhibition in neurodegenerative conditions
Chuang, D.-M., Leng, Y., Marinova, Z., Kim, H.-J., & Chiu, C.-T. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.06.002 · Cited by 676
“, sodium butyrate, 4phenylbutyrate, and TSA) potentiated these neuroprotective effects against excitotoxicity when used in conjunction with lithium, another mood stabilizer with a robust neuroprotective profile [34].”
BackgroundSelf-citationAkt/GSK3 Signaling in the Action of Psychotropic Drugs
Beaulieu, J.-M., Gainetdinov, R. R., & Caron, M. G. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.011008.145634 · Cited by 522
Therapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder
Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404
Self-citationEpigenetic regulation of gene expression in physiological and pathological brain processes
Gräff, J., Kim, D., Dobbin, M. M., & Tsai, L.-H. (2011) · Physiological Reviews · doi:10.1152/physrev.00012.2010 · Cited by 373
Machado‐Vieira, R., Manji, H. K., & Zarate Jr, C. A. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00714.x · Cited by 370
Metadata
- Authors
- Leng, Y., Liang, M.-H., Ren, M., Marinova, Z., Leeds, P., & Chuang, D.-M.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2008-03-05
- Volume
- 28
- Issue
- 10
- Pages
- 2576-2588
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2034753731
- Cited by
- 214
- References
- 10
- FWCI
- 14.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synergistic Neuroprotective Effects of Lithium and Valproic Acid or Other Histone Deacetylase Inhibitors in Neurons: Roles of Glycogen Synthase Kinase-3 Inhibition. https://app.cochat.ai/papers/10.1523/jneurosci.5467-07.2008
- The paper
- Leng, Y., Liang, M.-H., Ren, M., Marinova, Z., Leeds, P., & Chuang, D.-M. (2008). Synergistic Neuroprotective Effects of Lithium and Valproic Acid or Other Histone Deacetylase Inhibitors in Neurons: Roles of Glycogen Synthase Kinase-3 Inhibition. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.5467-07.2008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.